Stem Point Capital LP Protagonist Therapeutics, Inc Transaction History
Stem Point Capital LP
- $314 Billion
- Q1 2025
A detailed history of Stem Point Capital LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Stem Point Capital LP holds 49,241 shares of PTGX stock, worth $2.51 Million. This represents 0.76% of its overall portfolio holdings.
Number of Shares
49,241
Previous 141,714
65.25%
Holding current value
$2.51 Million
Previous $5.47 Billion
56.47%
% of portfolio
0.76%
Previous 1.37%
Shares
3 transactions
Others Institutions Holding PTGX
# of Institutions
304Shares Held
61.4MCall Options Held
1.01MPut Options Held
555K-
Farallon Capital Management LLC San Francisco, CA6.11MShares$312 Million1.7% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$294 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.72MShares$292 Million4.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.28MShares$218 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$153 Million5.07% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.51B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...